The global immunotherapy drugs market is anticipated to grow at a CAGR of 9.0% during the forecast period. The increasing clinical trials to develop more immunotherapy drugs are a key factor driving the growth of the market. For instance, in July 2022, Sosei Group Corp., an international biopharmaceutical company and Cancer Research UK, the world’s largest private funder of cancer research signed an agreement to bring Sosei Heptares’ cancer immunotherapy drug candidate into a first-in-human trial. Under the Clinical Trial and Licence Agreement (CTLA), Cancer Research UK’s Centre for Drug Development will sponsor, design and execute a Phase I/IIa clinical trial of HTL00397322, a novel selective EP4 antagonist.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/immunotherapy-drugs-market
Sosei Heptares will be responsible for CTA enabling activities, including GLP toxicology, IMP manufacture1 and other necessary pre-clinical studies in preparation for the opening of the clinical trial. Sosei Heptares holds a license to the results generated under the trial to continue the clinical development and commercialization of HTL0039732. HTL0039732 has been proposed for a range of cancers including microsatellite stable3 colorectal, gastroesophageal, head and neck and castration- resistant prostate cancer.
In July 2022, Immunocare Holdings plc, a UK-based, commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases including cancer, autoimmune and infectious diseases, announced that its first patient has received new immunotherapy drug for HIV in the clinical trial. These clinical trials are offering an opportunity for the growth of the global immunotherapy drugs market.
Global Immunotherapy Drugs Market Report by Segment
By Type
- Monoclonal Antibodies
- Checkpoint Inhibitors
- Interferons & Interleukins
- Others
By Therapeutic Application
- Cancer
- Infectious Diseases
- Autoimmune & Inflammatory
- Others
By End-User
- Hospitals
- Clinics
- Others
A full report of Immunotherapy Drugs Market is available at: https://www.omrglobal.com/industry-reports/immunotherapy-drugs-market
Immunotherapy Drugs Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca Plc
- Bayer AG
- BioNTech SE
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Inc.
- Hoffmann-La Roche Ltd.
- Genmab
- Gilead Sciences
- GlaxoSmithKline Plc
- Immatics Biotechnologies
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
Visit more report at
https://www.linkedin.com/pulse/scaffold-technology-market-size-trends-latest-arti-vishwakarma-mlsof/